Update on pharmacologic options for smoking cessation treatment.
paper
Cited
Public
Unavailable
- Authors
- Nides, Mitchell
- Year
- 2008
- Journal
- The American journal of medicine
- PMID
- 18342163
- DOI
- 10.1016/j.amjmed.2008.01.016
Although the proportion of the adult population in the United States that smokes has decreased steadily, the rate of successful quit attempts is still low. Smokers develop nicotine dependence that resembles other addictions, and may require multiple attempts and long-term treatment to sustain abstinence. Currently available first-line agents for smoking cessation therapy include nicotine replacement therapy, which is available in several formulations, including transdermal patch, gum, nasal spray, inhaler, and lozenge; bupropion, an atypical antidepressant; and varenicline, a partial agonist of the alpha(4)beta(2) nicotinic acetylcholine receptor that was recently developed and approved specifically for smoking cessation therapy. Second-line agents are nortriptyline, a tricyclic antidepressant agent, and clonidine, an antihypertensive drug. With the exception of varenicline, which has been shown to offer significant improvement in abstinence rates over bupropion, all of the available treatments appear similarly effective. However, the adverse event profiles of nortriptyline and clonidine make them more appropriate for second-line therapy, when first-line treatments have failed or are not tolerated. Rimonabant, a cannabinoid-1 receptor antagonist that was being developed for smoking cessation, received a nonapprovable letter from the FDA in 2006 and there is no further information as to whether development for this indication is continuing for this agent. Nicotine vaccines are under investigation and offer promise, especially for relapse prevention. Ultimately, selection of pharmacologic agent should be based on the patient's comorbidities and preferences, as well as on the agent's adverse event profile.
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | 2009 | 19016476 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Adapting a Functional Assessment of Cigarette Smoking for People with Intellectual and Developmental Disabilities. | Regnier SD et al. | β | 2025 | β |
| Cardiovascular Effects of Smoking and Smoking Cessation: A 2024 Update. | Rahman M et al. | β | 2025 | β |
| Predictors of quitting support from nonsmoking mothers for smoking fathers: a cross-sectional study from Chinese pupils' families. | Jiang N et al. | β | 2024 | β |
| Psychopharmacology of smoking cessation medications: focus on patients with mental health disorders. | Castaldelli-Maia JM et al. | β | 2023 | β |
| Modification effect of ideal cardiovascular health metrics on genetic association with incident heart failure in the China Kadoorie Biobank and the UK Biobank. | Yang R et al. | β | 2021 | β |
| Translational Research in Nicotine Addiction. | Fisher ML et al. | β | 2021 | β |
| Sensory experiences and cues among E-cigarette users. | DiPiazza J et al. | β | 2020 | β |
| A computerized exposure system for animal models to optimize nicotine delivery into the brain through inhalation of electronic cigarette vapors or cigarette smoke. | Alasmari F et al. | β | 2018 | β |
| Current and Emerging Pharmacotherapies for Cessation of Tobacco Smoking. | GΓ³mez-Coronado N et al. | β | 2018 | β |
| Neuregulin 3 Signaling Mediates Nicotine-Dependent Synaptic Plasticity in the Orbitofrontal Cortex and Cognition. | Zhou L et al. | β | 2018 | β |
| Clinical Effects of Cigarette Smoking: Epidemiologic Impact and Review of Pharmacotherapy Options. | Onor IO et al. | β | 2017 | β |
| Healthcare financing systems for increasing the use of tobacco dependence treatment. | van den Brand FA et al. | β | 2017 | β |
| Study of monotherapy versus combination therapy for tobacco dependence among heavily addicted smokers. | Ternullo SR et al. | β | 2017 | β |
| Trends in utilization of smoking cessation agents before and after the passage of FDA boxed warning in the United States. | Shah D et al. | β | 2017 | β |
| Helping patients to reduce tobacco consumption in oncology: a narrative review. | Lucchiari C et al. | β | 2016 | β |
| Neuroscience of nicotine for addiction medicine: novel targets for smoking cessation medications. | D'Souza MS | β | 2016 | β |
| Patterns of nicotine dependence in four Eastern European countries. | Kaleta D et al. | β | 2015 | β |
| Risk of Heart Failure and Death After Prolonged Smoking Cessation: Role of Amount and Duration of Prior Smoking. | Ahmed AA et al. | β | 2015 | β |
| Donepezil reverses nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6J mice. | Poole RL et al. | β | 2014 | β |
| Involvement of glutamatergic and GABAergic systems in nicotine dependence: Implications for novel pharmacotherapies for smoking cessation. | Li X et al. | β | 2014 | β |
| Involvement of neuronal Ξ²2 subunit-containing nicotinic acetylcholine receptors in nicotine reward and withdrawal: implications for pharmacotherapies. | Simmons SJ et al. | β | 2014 | β |
| Pharmacotherapy for smoking cessation: pharmacological principles and clinical practice. | Aubin HJ et al. | β | 2014 | β |
| Smoking cessation effectiveness in smokers with COPD and asthma under real life conditions. | Gratziou Ch et al. | β | 2014 | β |
| TRP modulation by natural compounds. | Meotti FC et al. | β | 2014 | β |
| Collaborative care for depression: a literature review and a model for implementation in developing countries. | Farooq S | β | 2013 | β |
| Medications for substance use disorders. | Douaihy AB et al. | β | 2013 | β |
| Pharmacological intervention of nicotine dependence. | Jain R et al. | β | 2013 | β |
| Pharmacotherapies and harm-reduction options for the treatment of tobacco dependence. | Le Houezec J et al. | β | 2013 | β |
| Predictors of success in smoking cessation among Italian adults motivated to quit. | Iliceto P et al. | β | 2013 | β |
| Reinstatement of nicotine seeking is mediated by glutamatergic plasticity. | Gipson CD et al. | β | 2013 | β |
| Suppression of nicotine-induced pathophysiology by an adenovirus hexon-based antinicotine vaccine. | Rosenberg JB et al. | β | 2013 | β |
| The first 7 days of a quit attempt predicts relapse: validation of a measure for screening medications for nicotine dependence. | Ashare RL et al. | β | 2013 | β |
| Translational research in nicotine dependence. | Turner JR et al. | β | 2013 | β |
| A Preliminary Feasibility Study of Varenicline for Smoking Cessation in Bipolar Disorder. | Wu BS et al. | β | 2012 | β |
| Healthcare financing systems for increasing the use of tobacco dependence treatment. | Reda AA et al. | β | 2012 | β |
| The duration of nicotine withdrawal-associated deficits in contextual fear conditioning parallels changes in hippocampal high affinity nicotinic acetylcholine receptor upregulation. | Gould TJ et al. | β | 2012 | β |
| The return on investment of a Medicaid tobacco cessation program in Massachusetts. | Richard P et al. | β | 2012 | β |
| A discrete-event simulation of smoking-cessation strategies based on varenicline pivotal trial data. | Xenakis JG et al. | β | 2011 | β |
| Catalytic mechanism of cytochrome P450 for 5'-hydroxylation of nicotine: fundamental reaction pathways and stereoselectivity. | Li D et al. | β | 2011 | β |
| Effectiveness of varenicline for smoking cessation: a 1-year follow-up study. | Grassi MC et al. | β | 2011 | β |
| Neuronal mechanisms underlying development of nicotine dependence: implications for novel smoking-cessation treatments. | D'Souza MS et al. | β | 2011 | β |
| [Pharmacotherapeutic treatment strategies for smoking cessation]. | Vasic N et al. | β | 2011 | β |
| Pharmacotherapy for smoking cessation: current advances and research topics. | Raupach T et al. | β | 2011 | β |
| Repeated administration of the GABAB receptor positive modulator BHF177 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine seeking in rats. | Vlachou S et al. | β | 2011 | β |
| The effects of galantamine on nicotine withdrawal-induced deficits in contextual fear conditioning in C57BL/6 mice. | Wilkinson DS et al. | β | 2011 | β |
| The monoamine oxidase (MAO) inhibitor tranylcypromine enhances nicotine self-administration in rats through a mechanism independent of MAO inhibition. | Lotfipour S et al. | β | 2011 | β |
| Current treatment options in smoking cessation. | Crain D et al. | β | 2010 | β |
| Fundamental reaction pathways for cytochrome P450-catalyzed 5'-hydroxylation and N-demethylation of nicotine. | Li D et al. | β | 2010 | β |
| Inflammatory and autoimmune reactions in atherosclerosis and vaccine design informatics. | Jan M et al. | β | 2010 | β |
| Is the personality characteristic "impulsive sensation seeking" correlated to differences in current smoking between ulcerative colitis and Crohn's disease patients? | Hyphantis T et al. | β | 2010 | β |
| Pharmacogenetics of smoking cessation therapy. | Kortmann GL et al. | β | 2010 | β |
| Randomized, controlled, double-blind trial of taranabant for smoking cessation. | Morrison MF et al. | β | 2010 | β |
| The 10 most important things known about addiction. | Sellman D | β | 2010 | β |
| Baclofen prevents drug-induced reinstatement of extinguished nicotine-seeking behaviour and nicotine place preference in rodents. | Fattore L et al. | β | 2009 | β |
| Cellular events in nicotine addiction. | Penton RE et al. | β | 2009 | β |
| Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation--results from four European countries. | Bolin K et al. | β | 2009 | β |
| Evidence for association between polymorphisms in the cannabinoid receptor 1 (CNR1) gene and cannabis dependence. | Agrawal A et al. | β | 2009 | β |
| Gender differences in self-reported use, perceived efficacy, and interest in future use of nicotine-dependence treatments: A cross-sectional survey in adults at a tertiary care center for nicotine dependence. | Narayanan S et al. | β | 2009 | β |
| Healthcare financing systems for increasing the use of tobacco dependence treatment. | Reda AA et al. | β | 2009 | β |
| Nicotine activates the chemosensory cation channel TRPA1. | Talavera K et al. | β | 2009 | β |
| Pharmacotherapy of addictive disorders. | Ross S et al. | β | 2009 | β |
| Rimonabant: a rapidly expanding role in the management of metabolic and systemic disorders besides polycystic ovarian syndrome. | Kapoor S | β | 2009 | β |
| Smoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 century. | Laniado-LaborΓn R | β | 2009 | β |
| Smoking and depression: Is smoking cessation effective? | Ischaki E et al. | β | 2009 | β |
| Smoking cessation: it is never too late. | Nilsson PM et al. | β | 2009 | β |
| What do we know about the role of pharmacotherapy for smoking cessation before or during pregnancy? | Oncken CA et al. | β | 2009 | β |
| Neurobiology of nicotine addiction: implications for smoking cessation treatment. | Benowitz NL | β | 2008 | β |
| Nicotinic receptor partial agonists as novel compounds for the treatment of smoking cessation. | Tutka P | β | 2008 | β |
| Nonpharmacologic therapy for smoking cessation: characteristics and efficacy of current approaches. | Niaura R | β | 2008 | β |
| Smoking, health and ageing. | Nicita-Mauro V et al. | β | 2008 | β |
| Therapy for Cessation of Smoking. | Bhattacharyya D et al. | β | 2008 | β |
| Tobacco use and comorbidity in bulimia nervosa. | Sandager N et al. | β | 2008 | β |
| Vaccines in development to prevent and treat atherosclerotic disease. | Riley E et al. | β | 2008 | β |